Improving immunotherapy in solid tumors using FMT

A study published in Cell reports that fecal microbiota transplantation (FMT) significantly enhances the efficacy of first-line immune checkpoint inhibitors across multiple solid tumor types, including renal cell carcinoma, cutaneous melanoma, and non-small cell lung cancer. Clinical trial data showed that the benefit was achieved with an acceptable safety profile and appeared to be mediated by functional remodeling of the gut microbiome, depletion of harmful bacterial taxa, and systemic immunometabolic modulation. The findings strengthen the rationale for microbiome-directed therapeutic strategies as a complement to existing cancer immunotherapy regimens. Published in a top-tier journal, the work marks an important step toward integrating microbiome interventions into standard oncology care pathways.